Blake Choplin, MD
Pulmonary Disease · Pittsburgh, PANPI 1174918288
Payments from drug & device makers
Across 34 payments — averaging $35.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus Corporation Of The Americas$582
- GSK$141
- Novartis$117
- ZOLL Respicardia, Inc.$83
- AstraZeneca$75
- Takeda Pharmaceuticals U.S.A., Inc.$66
- plus $158 from 6 others
What the payments were for
- Travel & lodging$47239%
- Food & beverage$74961%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus Corporation Of The Americas | 5 | $582 |
| GSK | 10 | $141 |
| Novartis | 5 | $117 |
| ZOLL Respicardia, Inc. | 1 | $83 |
| AstraZeneca | 4 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $66 |
| Regeneron Healthcare Solutions, Inc. | 2 | $49 |
| Jazz Pharmaceuticals Inc. | 1 | $31 |
| Amgen | 1 | $27 |
| Boehringer Ingelheim | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,221 in reported general payments places this provider in the 45th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 86 | $66,886 |
| Dupixent PenDupilumab | 11 | $39,534 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 48 | $31,828 |
| Breo ElliptaFluticasone/Vilanterol | 48 | $26,559 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 45 | $25,359 |
| DuleraMometasone/Formoterol | 53 | $17,688 |
| Spiriva RespimatTiotropium Bromide | 24 | $13,116 |
| Advair HfaFluticasone Propion/Salmeterol | 21 | $6,383 |
| Fluticasone Propionate HfaFluticasone Propionate | 18 | $5,518 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 49 | $5,217 |
| BreynaBudesonide/Formoterol Fumarate | 18 | $3,630 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $3,457 |
| Ventolin HfaAlbuterol Sulfate | 21 | $1,560 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 36 | $1,316 |
| Pantoprazole Sodium | 28 | $520 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $141 | $93,444134 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $19 | $38,47569 claims |
| AstraZenecaBreztri Aerosphere | $75 | $31,82848 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Pittsburgh
- Kevin GibsonPittsburgh$1.3M
- Frank SciurbaPittsburgh$1.2M
- Joseph PilewskiPittsburgh$1M
- Steven DuncanPittsburgh$995K
- Tariq CheemaPittsburgh$907K
- Sally WenzelPittsburgh$676K
- Chadi HagePittsburgh$479K
- Stephen BashedaPittsburgh$456K
- Alison GimbelPittsburgh$304K
- Georgios KitsiosPittsburgh$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.